## 13(S)-HODE: A Fatty Acid with Potential Research Significance
**13(S)-HODE**, or **13(S)-hydroxyoctadecadienoic acid**, is a **fatty acid** produced from the **enzymatic oxidation of linoleic acid**, a common polyunsaturated fatty acid found in vegetable oils.
**Here's why it's important for research:**
* **Inflammation and Immune Response:** 13(S)-HODE is a key player in the **inflammatory response** and is produced by **lipoxygenases**, enzymes involved in the metabolism of fatty acids. Its role in immune signaling makes it a focus for research in **autoimmune diseases**, **allergies**, and **inflammatory bowel disease.**
* **Cancer Research:** 13(S)-HODE has been linked to **cancer cell growth and progression** in some studies. Researchers are investigating its potential as a **biomarker** for cancer diagnosis and prognosis and exploring its potential therapeutic applications in cancer treatment.
* **Cardiovascular Health:** 13(S)-HODE is also being studied for its role in **cardiovascular health**. It has been linked to **blood pressure regulation**, **blood clotting**, and **atherosclerosis**. Its potential impact on heart disease and stroke is under investigation.
* **Neurological Function:** Emerging research suggests that 13(S)-HODE may play a role in **neurological function**. Studies are exploring its potential involvement in **neuroinflammation**, **neurodegenerative diseases**, and **brain development**.
* **Metabolic Syndrome:** 13(S)-HODE's impact on **insulin sensitivity** and **glucose metabolism** is being investigated. Researchers are exploring its potential involvement in **obesity** and **type 2 diabetes**.
**Overall, 13(S)-HODE is a fascinating molecule with potential implications for various biological processes.** Researchers continue to uncover its complex roles and its possible application in treating a wide range of diseases.
**It's important to note:**
* More research is needed to fully understand the role of 13(S)-HODE in various physiological processes and its potential therapeutic value.
* The complexity of 13(S)-HODE's involvement in various pathways necessitates cautious interpretation of research findings.
By further investigating 13(S)-HODE, researchers may develop new diagnostic tools and therapeutic interventions for numerous diseases.
13(S)-HODE : An HODE (hydroxyoctadecadienoic acid) in which the double bonds are at positions 9 and 11 (E and Z geometry, respectively) and the hydroxy group is at position 13 (with S-configuration). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 6443013 |
| CHEMBL ID | 451721 |
| CHEBI ID | 34154 |
| SCHEMBL ID | 287628 |
| Synonym |
|---|
| CHEBI:34154 , |
| (9z, 11e)-(13s)-13-hydroxyoctadeca-9,11-dienoic acid |
| 29623-28-7 |
| (r-(e,z))-13-hydroxy-9,11-octadecadienoic acid |
| (9z,11e,13s)-13-hydroxyoctadeca-9,11-dienoic acid |
| 13(s)-hydroxy-9(z),11(e)-octadecadienoic acid |
| 13-hydroxyoctadecadienoic acid |
| SPECTRUM5_002049 |
| BSPBIO_001325 |
| IDI1_033795 |
| (9z,11e)-(13s)-13-hydroxyoctadeca-9,11-dienoic acid |
| (13s)-hydroxyoctadecadienoic acid |
| 13(s)-hode |
| 13(s)-hydroxyoctadeca-9z,11e-dienoic acid, 90-100 mug/ml in ethanol, >=98% |
| NCGC00161318-01 |
| NCGC00161318-03 |
| NCGC00161318-02 |
| NCGC00161318-04 |
| 13(s)-hydroxyoctadeca-9z,11e-dienoic acid |
| 13s-hydroxyoctadecadienoic acid |
| 10219-69-9 |
| HMS1989C07 |
| DB06926 |
| BML2-D06 |
| HMS1791C07 |
| HMS1361C07 |
| (s)-coriolic acid |
| CHEMBL451721 , |
| unii-53cyy2a5pm |
| l-113-hydroxy-cis-9,trans-11-octadecadienoic acid |
| 53cyy2a5pm , |
| coriolic acid, (+)- |
| 13s-hode |
| 13s-hydroxy-9z,11e-octadecadienoic acid |
| LMFA02000228 |
| bdbm50367479 |
| BRD-K86465814-001-01-1 |
| SCHEMBL287628 |
| HMS3402C07 |
| (+/-)-coriolic acid |
| AKOS027378814 |
| 13(s) hode |
| (13s)-hydroxyoctadecadienoate |
| 13-hydroxyoctadecadienoate |
| 13(s)-hydroxy-(z,e)-9,11-octadecadienoic acid |
| sr-01000947026 |
| SR-01000947026-1 |
| Q21099640 |
| DTXSID201017286 |
| (9z,11e,13s)-13-hydroxy-9,11-octadecadienoic acid |
| 9,11-octadecadienoic acid, 13-hydroxy-, (9z,11e,13s)- |
| U2DA27TT5J , |
| 9,11-octadecadienoic acid, 13-hydroxy-, (9z,11e)- |
| 13-hydroxy-9,11-cis,trans-octadecadienoic acid |
| unii-u2da27tt5j |
| l-13-hydroxy-cis-9,trans-11-octadecadienoic acid |
| coriolic acid, (+/-)- |
| (+)-coriolic acid |
| 9,11-octadecadienoic acid, 13-hydroxy-, (e,z)- |
| .alpha.-artemisolic acid |
| (s,9z,11e)-13-hydroxyoctadeca-9,11-dienoic acid |
| 13-hydroxy-9(z),11(e)-octadecadienoic acid |
| HY-113884B |
| STARBLD0018580 |
| CS-0138393 |
| PD005774 |
| Role | Description |
|---|---|
| mouse metabolite | Any mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus). |
| human xenobiotic metabolite | Any human metabolite produced by metabolism of a xenobiotic compound in humans. |
| antineoplastic agent | A substance that inhibits or prevents the proliferation of neoplasms. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| HODE | Hydroxy-octadecadienoic acids, formed in mammalian cells from the corresponding hydroperoxy compounds (HPODEs). |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Pathway | Proteins | Compounds |
|---|---|---|
| Linoleic acid oxylipin metabolism | 0 | 13 |
| Octadecanoid formation from linoleic acid | 0 | 28 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 56.2341 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
| TDP1 protein | Homo sapiens (human) | Potency | 27.5110 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| regulator of G-protein signaling 4 | Homo sapiens (human) | Potency | 6.7016 | 0.5318 | 15.4358 | 37.6858 | AID504845 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 39.8107 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Polyunsaturated fatty acid 5-lipoxygenase | Rattus norvegicus (Norway rat) | IC50 (µMol) | 82.0000 | 0.0046 | 2.0182 | 10.0000 | AID6794 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID356303 | Induction of NADPH:quinone reductase activity in mouse Hepa-1c1c7 cells assessed as drug level required to double specific enzyme activity | 2003 | Journal of natural products, Aug, Volume: 66, Issue:8 | Isolation and characterization of miscellaneous secondary metabolites of Deprea subtriflora. |
| AID6794 | Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase | 1987 | Journal of medicinal chemistry, Feb, Volume: 30, Issue:2 | Structural requirements for the inhibition of 5-lipoxygenase by 15-hydroxyeicosa-5,8,11,13-tetraenoic acid analogues. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.19) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||